Loading...

RadNet, Inc.

RDNTNASDAQ
Healthcare
Medical - Diagnostics & Research
$70.10
$1.49(2.17%)

RadNet, Inc. (RDNT) Financial Performance & Income Statement Overview

View comprehensive annual and quarterly summaries for RadNet, Inc. (RDNT), featuring income statements, balance sheets, and cash flow data.

Revenue Growth
13.18%
13.18%
Operating Income Growth
6.002%
6.002%
Net Income Growth
-8.25%
8.25%
Operating Cash Flow Growth
5.51%
5.51%
Operating Margin
3.42%
3.42%
Gross Margin
30.28%
30.28%
Net Profit Margin
-0.78%
0.78%
ROE
-1.64%
1.64%
ROIC
2.20%
2.20%

RadNet, Inc. (RDNT) Income Statement & Financial Overview

View the income breakdown for RadNet, Inc. RDNT across both annual and quarterly reports.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$471.40M$477.10M$461.14M$459.71M
Cost of Revenue$453.48M$411.44M$148000.00$424.20M
Gross Profit$17.92M$65.67M$460.99M$35.52M
Gross Profit Ratio$0.04$0.14$1.00$0.08
R&D Expenses$0.00$0.00$0.00$3.32M
SG&A Expenses$0.00$0.00$0.00$29.90M
Operating Expenses$42.02M$41.14M$427.23M$34.48M
Total Costs & Expenses$495.50M$452.58M$427.23M$424.20M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$17.24M$18.07M$19.43M$26.08M
Depreciation & Amortization$35.48M$96.57M$391.80M$34.48M
EBITDA$19.59M$129.97M$427.82M$69.99M
EBITDA Ratio$0.04$0.27$0.93$0.15
Operating Income-$24.10M$24.52M$33.91M$34.85M
Operating Income Ratio-$0.05$0.05$0.07$0.08
Other Income/Expenses (Net)-$9.03M-$9.20M-$17.32M-$25.45M
Income Before Tax-$33.13M$15.32M$16.59M$9.40M
Income Before Tax Ratio-$0.07$0.03$0.04$0.02
Income Tax Expense-$3.40M$1.10M-$4.33M$2.46M
Net Income-$37.93M$5.34M$20.93M-$2.98M
Net Income Ratio-$0.08$0.01$0.05-$0.006
EPS-$0.51$0.07$0.28-$0.04
Diluted EPS-$0.51$0.07$0.28-$0.04
Weighted Avg Shares Outstanding$74.38M$73.57M$73.49M$73.42M
Weighted Avg Shares Outstanding (Diluted)$74.38M$75.54M$75.17M$73.42M

Over the past four quarters, RadNet, Inc. demonstrated steady revenue growth, increasing from $459.71M in Q2 2024 to $471.40M in Q1 2025. Operating income reached -$24.10M in Q1 2025, maintaining a consistent -5% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $19.59M, reflecting operational efficiency. Net income dropped to -$37.93M, with EPS at -$0.51. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;